Current Sirolimus News and Events | Page 2

Current Sirolimus News and Events, Sirolimus News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 4 | 145 Results
Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation. (2012-06-26)

BWH Center for LAM Research and Clinical Care awarded $1 million grant from Department of Defense
The Center for LAM Research and Clinical Care at Brigham and Women's Hospital has been awarded a $1 million plus, four-year grant from the US Department of Defense. (2012-02-07)

Results of the PEPCAD-DES trial reported at TCT 2011
A clinical trial of patients with restenosis in drug-eluting stents (DES) in native coronary arteries found that treatment with paclitaxel-coated balloon angioplasty demonstrated superior results over plain old uncoated-balloon angioplasty (POBA). Results from the PEPCAD-DES clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. (2011-11-11)

Results of the REMEDEE trial reported at TCT 2011
A randomized comparison of a dual therapy stent -- which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer -- with a paclitaxel-eluting stent showed that the dual therapy stent effectively controls neointimal proliferation and was shown to be safe and effective. Results of the REMEDEE trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. (2011-11-11)

CRF announces late-breaking trials and first report investigations to be presented at TCT 2011
Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in interventional cardiovascular medicine. (2011-09-15)

An 'important' reduction in risk of stent thrombosis with everolimus-eluting stent
Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an (2011-08-30)

Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent. (2011-08-29)

Best post-transplant drug regimen identified for patients with new kidneys
Patients treated with tacrolimus (TAC) and mycophenolate mofetil (MMF) had lower rejection rates and better kidney function. Multi-year study compared three commonly used immunosuppresive regimens. More than 16,000 US patients receive kidney transplants each year; preventing rejection requires a life-long delicate balance of medication (2011-07-29)

Late-breaking clinical trials
Results from C91 (2011-05-17)

OHSU expert co-authors study finding treatment for rare lung disease
A new study has revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women. (2011-04-11)

Sirolimus therapy alleviates symptoms of lung disease LAM
Sirolimus, a drug currently used to help prevent transplant rejection, can improve lung function and quality of life in individuals living with the lung disease lymphangioleiomyomatosis (LAM), according to the results of a new study sponsored and conducted in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. (2011-03-16)

New therapy found for rare lung disorder
Researchers at the University of Cincinnati and Cincinnati Children's Hospital Medical Center have found that the FDA-approved drug sirolimus, used primarily to prevent rejection in organ transplant patients, stabilized lung function in women with lymphangioleiomyomatosis. (2011-03-16)

Sunlight can influence the breakdown of medicines in the body
A study from the Swedish medical university Karolinska Institutet has shown that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons. The findings offer a completely new model to explain individual differences in the effects of drugs, and how the surroundings can influence the body's ability to deal with toxins. (2011-03-09)

Leaders trial: 3-year data on stent with biodegradable polymer to be presented at TCT 2010
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2010-09-21)

New stent design demonstrates superiority at 6 months; 1 year data to be presented at TCT 2010
A new drug-eluting stent design demonstrated superiority over a traditional drug-eluting stent at six months, according to a study led by Laura Mauri, M.D., associate professor of medicine, Brigham and Women's Hospital, Harvard Medical School. The study is being presented at the 22nd annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2010-09-21)

Study examines use of stent with bioabsorbable polymer
Three-year data demonstrated that satisfactory clinical and safety outcomes of sirolimus eluting stents with a biodegradable polymer were sustained in a real world setting. The results were presented at the 22nd annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2010-09-21)

TCT 2010 late breaking trials to have impact on practice of interventional cardiology
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiovascular medicine. Now in its 22nd year, it is the world's largest privately run medical conference and attended by more than 10,000 participants each year. TCT 2010 will be held Sept. 21-25 in Washington, D.C. (2010-09-07)

CRF announces featured clinical trials to be presented at TCT 2010
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiovascular medicine. Now in its 22nd year, it is the world's largest privately run medical conference and attended by more than 10,000 participants each year. TCT 2010 will be held Sept. 21-25 in Washington, D.C. (2010-08-12)

CRF announces late breaking trials and first report investigations to be presented at TCT 2010
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiovascular medicine. Now in its 22nd year, it is the world's largest privately run medical conference and attended by more than 10,000 participants each year. TCT 2010 will be held Sept. 21-25 in Washington, D.C. (2010-08-05)

Post-transplant drug may also help patients with common genetic kidney disease
The immunosuppressive drug sirolimus considerably improves the kidney health of patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that this agent may be a promising treatment option for patients with ADPKD -- the most common genetic kidney disease and a major cause of kidney failure. (2010-05-13)

New therapies increase survival rates in post-transplant liver cancer patients
A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases. (2010-03-25)

Sirolimus-eluting stent better than zotarolimus-eluting stent in everyday clinical practice
The widely used sirolimus-eluting stent is superior to the second-generation zotarolimus-eluting stent for patients in everyday clinical practice, concludes the SORT OUT III study published online first and in this week's edition of the Lancet. (2010-03-15)

Research at UCSB points to potential treatment for kidney disease
Research performed at UC Santa Barbara points to the drug rapamycin as a potential treatment for kidney disease. The study builds on past research and shows that studies performed on mice are more likely to translate to humans than previously thought. The results are published in the current online issue of the Journal of the American Society of Nephrology. (2010-01-25)

Everolimus-eluting stent better than paclitaxel-eluting stent in unselected patients
The everolimus-eluting stent is better than the second generation paclitaxel-eluting stent in unselected patients undergoing percutaneous coronary intervention in terms of safety and efficacy, concludes the COMPARE study, published online first and in an upcoming edition of the Lancet. (2010-01-07)

Blood stem cell transplant regimen reverses sickle cell disease in adults
A modified blood adult stem cell transplant regimen has effectively reversed sickle cell disease in nine of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine. (2009-12-11)

Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients
A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's annual meeting on Sunday, Dec. 6. (2009-12-06)

Switching immunosuppressants reduces cancer risk in kidney
Switching to a newer type of immunosuppressant drug may reduce the high rate of skin cancer after kidney transplantation, according to research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, Calif. (2009-10-31)

Press alert for American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition
During ASN's 42nd Annual Meeting and Scientific Exposition, the Society will present research on the latest issues and scientific breakthroughs in nephrology. (2009-10-20)

Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2009-09-21)

Drug-eluting stents safe, effective for treatment of chronic total occlusions
A multicenter study in Asia found drug-eluting stents effective with a low rate of acute complications in patients with chronic total occlusions undergoing PCI. Results of the study will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2009-09-21)

New type of sirolimus-eluting stent demonstrates superior results
A new type of sirolimus-eluting stent successfully showed significantly greater neointimal suppression than the paclitaxel-eluting stent with greater vessel wall integrity surrounding the stent, confirming the finding of superiority of the SES over the PES stent for the trial's primary endpoint of in-stent late loss. (2009-09-21)

Press conference schedule announced for TCT 2009
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiology. Now in its 21st year, it is the world's largest privately-run medical conference and attended by more than 10,000 participants each year. TCT 2009 will be held Sept. 21-25 in San Francisco, Calif. (2009-08-27)

CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
Transcatheter Cardiovascular Therapeutics is the annual Scientific Symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiology. Now in its 21st year, it is the world's largest privately-run medical conference and attended by more than 10,000 participants each year. TCT 2009 will be held Sept. 21-25 in San Francisco, Calif. (2009-08-20)

CRF announces late breaking trials to be presented at TCT 2009 in San Francisco
Transcatheter Cardiovascular Therapeutics is the annual Scientific Symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiology. Now in its 21st year, it is the world's largest privately run medical conference and attended by more than 10,000 participants each year. TCT 2009 will be held Sept. 21-25 in San Francisco, Calif. (2009-08-12)

Finding key to cancer drug Gleevec's limitations
Researchers have learned why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends. The U-M team is now combining imatinib with other drugs in mouse studies to find ways to sensitize resistant leukemia-initiating cells to imatinib and enhance its power. (2009-08-04)

REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled (2009-06-01)

Grapefruit juice boosts drug's anti-cancer effects
Results from a small, early clinical trial show that combining grapefruit juice with the drug rapamycin can be effective in treating various types of cancer. The grapefruit juice increases drug levels, allowing lower doses of the drug to be given. (2009-04-20)

Patent pending for pain-free method of monitoring drug levels in transplant patients
The US Patent and Trademark Office is reviewing a University of Rhode Island pharmacy professor's proposal to use saliva as a non-invasive way to monitor concentrations of anti-rejection drugs in patients that undergo transplants. (2009-04-03)

Promising 3-year data: Saving limbs with drug-eluting stents
Attempts to treat critical limb ischemia in peripheral arterial disease patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation. (2009-03-10)

Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. Work at Columbia University Medical Center could potentially improve outcomes in diabetics who get stents. Though drug-eluting stents reduce the chance coronary arteries will become blocked again, clogged stents are still more common in diabetic patients than in the general population. (2008-12-17)

Page 2 of 4 | 145 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.